IGF1R and breast carcinoma: In reviewing anti-IGF therapeutics in breast cancer, Yee suggested that failure of the first generation of IGF1R inhibitors has unfairly reduced confidence in their use and that, as we learn from these mistakes, the death knell for these inhibitors may have been premature24.